Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice

被引:66
作者
Contentti, Edgar Carnero [1 ]
Ignacio Rojas, Juan [2 ,3 ]
Cristiano, Edgardo [2 ]
Daccach Marques, Vanessa [4 ]
Flores-Rivera, Jose [5 ]
Lana-Peixoto, Marco [6 ]
Navas, Carlos [7 ]
Papais-Alvarenga, Regina [8 ]
Sato, Douglas K. [9 ]
Soto de Castillo, Ibis [10 ]
Correale, Jorge [11 ]
机构
[1] Hosp Aleman, Dept Neurosci, Neuroimmunol Unit, Av Pueyrredon 1640,C1118AAT, Buenos Aires, DF, Argentina
[2] Ctr Esclerosis Multiple Buenos Aires CEMBA, Buenos Aires, DF, Argentina
[3] Hosp Univ CAMIC, Neurol Serv, Buenos Aires, DF, Argentina
[4] Univ Sao Paulo, Ribeirao Preto Med Sch, Hosp Clin, Dept Neurosci & Behav Sci, Sao Paulo, Brazil
[5] ABC Med Ctr, Natl Inst Neurol & Neurosurg, Mexico City, DF, Mexico
[6] Univ Fed Minas Gerais, Med Sch, Dept Neurol, Belo Horizonte, MG, Brazil
[7] Clin Univ Colombia, Clin Enfermedad Desmielinizante, Bogota, Colombia
[8] Univ Rio de Janeiro UNIRIO, Hosp Lagoa, Rio De Janeiro, Brazil
[9] Pontifical Catholic Univ Rio Grande do Sul PUCRS, Brain Inst Rio Grande do Sul, Porto Alegre, RS, Brazil
[10] Hosp Univ Maracaibo, Neurol Dept, Maracaibo, Venezuela
[11] Fleni, Dept Neurol, Montaneses 2325,C1428AQL, Buenos Aires, DF, Argentina
关键词
Neuromyelitis optica spectrum disorder; Consensus recommendations; Diagnosis; Antibody testing; Latin America; Clinical practice; CENTRAL VEIN SIGN; LONG-TERM COURSE; MULTIPLE-SCLEROSIS; MYCOPHENOLATE-MOFETIL; PLASMA-EXCHANGE; DIAGNOSTIC-CRITERIA; NMO-IGG; ANTI-AQUAPORIN-4; ANTIBODY; TREATMENT OUTCOMES; BRAZILIAN PATIENTS;
D O I
10.1016/j.msard.2020.102428
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: During the last two decades, neuromyelitis optica spectrum disorder (NMOSD) has undergone important changes, with new diagnostic markers and criteria, better recognition of clinical phenotypes, better disease prognosis and new therapeutic approaches. Consequently, management of NMOSD patients in Latin American (LATAM) has become more complex and challenging in clinical practice. In making these consensus recommendations, the aim was to review how the disease should be managed and treated among LATAM patients, in order to improve long-term outcomes in these populations. Methods: A panel of LATAM neurologists who are experts in demyelinating diseases and dedicated to management and care of NMOSD patients gathered virtually during 2019 and 2020 to make consensus recommendations on management and treatment of NMOSD patients in LATAM. To achieve this consensus, the RAND/UCLA methodology for reaching formal consensus was used. Results: The recommendations focused on diagnosis and differential diagnoses, disease prognosis, tailored treatment, identification of suboptimal treatment response and special circumstances management. They were based on published evidence and expert opinions. Conclusions: The recommendations of these consensus guidelines seek to optimize management and specific treatment of NMOSD patients in LATAM
引用
收藏
页数:18
相关论文
共 192 条
[1]   Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange [J].
Abboud, Hesham ;
Petrak, Alex ;
Mealy, Maureen ;
Sasidharan, Sarana ;
Siddique, Laila ;
Levy, Michael .
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (02) :185-192
[2]  
Alonso Veronica R., 2018, Central Nervous System Agents in Medicinal Chemistry, V18, P4, DOI 10.2174/1871524916666160229115047
[3]  
Alvarenga M P, 2017, Mult Scler J Exp Transl Clin, V3, p2055217317730098, DOI 10.1177/2055217317730098
[4]   Optic neuritis at disease onset predicts poor visual outcome in neuromyelitis optica spectrum disorders [J].
Amaral, Juliana M. S. S. ;
Talim, Natalia ;
Kleinpaul, Rodrigo ;
Lana-Peixoto, Marco A. .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 41
[5]   Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica A pilot study [J].
Araki, Manabu ;
Matsuoka, Takako ;
Miyamoto, Katsuichi ;
Kusunoki, Susumu ;
Okamoto, Tomoko ;
Murata, Miho ;
Miyake, Sachiko ;
Aranami, Toshimasa ;
Yamamura, Takashi .
NEUROLOGY, 2014, 82 (15) :1302-1306
[6]  
Asseyer Susanna, 2018, Mult Scler J Exp Transl Clin, V4, p2055217318796684, DOI 10.1177/2055217318796684
[7]   Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment [J].
Banerjee, Aditya ;
Ng, Jennifer ;
Coleman, Jessica ;
Ospina, Juan Pablo ;
Mealy, Maureen ;
Levy, Michael .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 28 :60-63
[8]   Impact of rituximab on relapse rate and disability in neuromyelitis optica [J].
Bedi, Gurdesh S. ;
Brown, Andrew D. ;
Delgado, Sylvia R. ;
Usmani, Nida ;
Lam, Byron L. ;
Sheremata, William A. .
MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (10) :1225-1230
[9]   Neuromyelitis optica spectrum disorder Patient experience and quality of life [J].
Beekman, Janine ;
Keisler, Aysha ;
Pedraza, Omar ;
Haramura, Masayuki ;
Gianella-Borradori, Athos ;
Katz, Eliezer ;
Ratchford, John N. ;
Barron, Gerard ;
Cook, Lawrence J. ;
Behne, Jacinta M. ;
Blaschke, Terrence F. ;
Smith, Terry J. ;
Yeaman, Michael R. .
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2019, 6 (04)
[10]   Tools for measuring patient safety in primary care settings using the RAND/UCLA appropriateness method [J].
Bell, Brian G. ;
Spencer, Rachel ;
Avery, Anthony J. ;
Campbell, Stephen M. .
BMC FAMILY PRACTICE, 2014, 15